European-based biotechnology company Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) announced on Monday that it has received the first instalment of EUR336,467 from a previously announced EUR4m non-dilutive grant awarded by the Wallonia Region of Belgium.

The funding forms part of a three-year development programme aligned with the company's roadmap for GF-1002 in metabolic dysfunction-associated steatohepatitis and will support ongoing development of its lead gene therapy candidate. Further instalments are expected in line with agreed milestones, with the initial payment allocated to eligible project activities.

Genflow Biosciences, founded in 2020 and headquartered in the UK with research and development facilities in Belgium, is focused on gene therapies targeting ageing. Its lead candidate, GF-1002, delivers a proprietary variant of the SIRT6 gene and is currently under evaluation in a randomised, blinded study in aged dogs, with interim results indicating improved survival, favourable safety and positive functional outcomes. The company is also advancing plans to assess GF-1002 in clinical development for metabolic dysfunction-associated steatohepatitis.